3,5,3'-Triiodothyronine-Loaded Liposomes Inhibit Hepatocarcinogenesis
3,5,3′-triiodothyronine
hepatocarcinogenesis
inflammation
liposome
macrophage
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
02
2022
accepted:
04
04
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is inflammation-related cancer. Persistent inflammatory injury of the liver is an important factor mediating the occurrence and development of liver cancer. Hepatic macrophages play an important role in the inflammatory microenvironment, which mediates tumor immune escape, tumor growth, and metastasis. Previous studies have suggested that L-3,5,3-triiodothyronine (T3) can regulate inflammation; however, its use is associated with serious cardiac side effects, and its role in hepatocarcinogenesis remains unclear. In this study, we aimed to develop an effective T3 delivery system with reduced cardiac toxicity and to explore its effects on HCC occurrence. T3 liposomes (T3-lipo) were prepared using the thin-film hydration method, and their characteristics, including particle size, polydispersity index, zeta potential, encapsulation efficiency, drug loading, drug release, and stability, were evaluated Compared with T3, T3-lipo had an enhanced inhibitory effect on hepatocarcinogenesis and reduced cardiac side effects in DEN-induced primary HCC in rats. Mechanistically, T3-lipo were absorbed by hepatic macrophages and regulated the secretion of inflammatory cytokines in macrophages by inhibiting inflammatory signaling pathways. T3-lipo may suppress hepatocarcinogenesis by regulating the inflammatory microenvironment in the liver and reduce the cardiac side effects meanwhile.
Sections du résumé
Background
UNASSIGNED
Hepatocellular carcinoma (HCC) is inflammation-related cancer. Persistent inflammatory injury of the liver is an important factor mediating the occurrence and development of liver cancer. Hepatic macrophages play an important role in the inflammatory microenvironment, which mediates tumor immune escape, tumor growth, and metastasis. Previous studies have suggested that L-3,5,3-triiodothyronine (T3) can regulate inflammation; however, its use is associated with serious cardiac side effects, and its role in hepatocarcinogenesis remains unclear. In this study, we aimed to develop an effective T3 delivery system with reduced cardiac toxicity and to explore its effects on HCC occurrence.
Methods
UNASSIGNED
T3 liposomes (T3-lipo) were prepared using the thin-film hydration method, and their characteristics, including particle size, polydispersity index, zeta potential, encapsulation efficiency, drug loading, drug release, and stability, were evaluated
Results
UNASSIGNED
Compared with T3, T3-lipo had an enhanced inhibitory effect on hepatocarcinogenesis and reduced cardiac side effects in DEN-induced primary HCC in rats. Mechanistically, T3-lipo were absorbed by hepatic macrophages and regulated the secretion of inflammatory cytokines in macrophages by inhibiting inflammatory signaling pathways.
Conclusions
UNASSIGNED
T3-lipo may suppress hepatocarcinogenesis by regulating the inflammatory microenvironment in the liver and reduce the cardiac side effects meanwhile.
Identifiants
pubmed: 35646705
doi: 10.3389/fonc.2022.877982
pmc: PMC9135096
doi:
Types de publication
Journal Article
Langues
eng
Pagination
877982Informations de copyright
Copyright © 2022 Sun, Hou, Zhang, Zhang, Shao, Li, Zong, Li, Shi, Yang and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Angew Chem Int Ed Engl. 2016 Jun 27;55(27):7606-30
pubmed: 27226395
Int J Pharm. 2018 Feb 15;537(1-2):257-267
pubmed: 29294323
Thyroid. 2001 Aug;11(8):717-24
pubmed: 11525263
Nat Rev Cardiol. 2017 Jan;14(1):39-55
pubmed: 27811932
Biochem Biophys Res Commun. 2013 Sep 13;439(1):60-5
pubmed: 23958302
Cancer Treat Rev. 2012 May;38(3):218-25
pubmed: 21763074
J Clin Endocrinol Metab. 2014 Jul;99(7):2372-82
pubmed: 24654753
Int J Pharm. 2009 May 21;373(1-2):116-23
pubmed: 19429296
Cell Res. 2011 Jan;21(1):159-68
pubmed: 21187858
Oncotarget. 2017 Jul 18;8(29):47136-47153
pubmed: 28525367
Can J Physiol Pharmacol. 2018 Jun;96(6):603-610
pubmed: 29406830
Hepatology. 2007 Jan;45(1):170-7
pubmed: 17187421
Mar Drugs. 2020 Nov 26;18(12):
pubmed: 33255947
Molecules. 2018 Jul 27;23(8):
pubmed: 30060484
Front Immunol. 2020 Mar 04;11:218
pubmed: 32194546
J Clin Invest. 2012 Feb;122(2):586-99
pubmed: 22251704
Front Immunol. 2019 Dec 03;10:2852
pubmed: 31849997
Genes Dev. 2017 Feb 1;31(3):247-259
pubmed: 28223311
Clin Gastroenterol Hepatol. 2007 Jan;5(1):118-23
pubmed: 17008133
Kidney Int. 2006 Aug;70(3):523-8
pubmed: 16775599
Cell Death Differ. 2012 Nov;19(11):1802-14
pubmed: 22576662
Matrix Biol. 2019 Apr;77:4-22
pubmed: 29777767
Liver Cancer. 2013 Aug;2(3-4):367-83
pubmed: 24400224
J Hepatol. 2014 May;60(5):1090-6
pubmed: 24412603
J Hepatol. 2020 Jun;72(6):1159-1169
pubmed: 31954205
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):2002-2009
pubmed: 32699077
Oncol Rep. 2020 Oct;44(4):1686-1698
pubmed: 32945493
Hepatology. 2015 Jan;61(1):249-59
pubmed: 25156012
Colloids Surf B Biointerfaces. 2017 Oct 1;158:356-362
pubmed: 28719856
Cell Biochem Funct. 1995 Jun;13(2):141-7
pubmed: 7758149
Nat Rev Mol Cell Biol. 2006 Dec;7(12):897-908
pubmed: 17139330
Hepatology. 2009 May;49(5):1563-70
pubmed: 19399911
Am J Chin Med. 2019;47(7):1589-1609
pubmed: 31645122
Hepatology. 2012 Oct;56(4):1567-74
pubmed: 22378061
Int J Mol Sci. 2021 Nov 26;22(23):
pubmed: 34884625
Nano Today. 2015 Aug;10(4):487-510
pubmed: 26640510
Physiol Rev. 2001 Jul;81(3):1097-142
pubmed: 11427693
Virol J. 2020 Oct 20;17(1):157
pubmed: 33081802
Free Radic Res. 1997 Mar;26(3):267-79
pubmed: 9161848
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Mediators Inflamm. 2016;2016:6757154
pubmed: 27051079
Neoplasia. 2018 Jan;20(1):57-68
pubmed: 29195126
Swiss Med Wkly. 2011 May 10;141:w13197
pubmed: 21557112
Nat Rev Gastroenterol Hepatol. 2020 Mar;17(3):139-152
pubmed: 31792430
Front Immunol. 2020 Jan 28;10:3112
pubmed: 32047496
Am J Pathol. 2014 Jan;184(1):230-47
pubmed: 24215914
Cells. 2019 Sep 05;8(9):
pubmed: 31491903
Arch Pharm Res. 2018 Oct;41(10):995-1008
pubmed: 30099678
PLoS One. 2013 Aug 14;8(8):e70832
pubmed: 23967115
J Hepatol. 2000 Aug;33(2):183-8
pubmed: 10952235
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
Cell Biochem Funct. 2017 Jan;35(1):50-55
pubmed: 28083964
Science. 2007 Jul 6;317(5834):121-4
pubmed: 17615358
Nat Rev Gastroenterol Hepatol. 2016 Feb;13(2):88-110
pubmed: 26758786
Int J Gen Med. 2021 Sep 16;14:5711-5718
pubmed: 34557025
Nat Rev Immunol. 2017 May;17(5):306-321
pubmed: 28317925